News

  • Oct 5, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Honduras

  • Jun 21, 2016

    Circadin® is now reimbursed under a Temporary Recommendation for Use (RTU) in France for Children with Neurodevelopmental Disorders (Read more)

  • Mar 3, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Peru

  • Mar 2, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina

  • Jan 11, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in South Africa

  • Mar 2, 2015

    Vigisom® 2mg (prolonged-release melatonin) is now commercially available in Chile

  • Sep 7, 2014

    Circadin® receives marketing authorization in South Africa

  • Sep 1, 2014

    Circadin® receives marketing authorization in South Korea

  • Aug 27, 2014

    Neurim Pharmaceuticals initiates Phase III study of Paediatric Prolonged-Release Melatonin in children with Autistic Spectrum Disorders, suffering from sleep disturbances

  • Jun 19, 2014

    Neurim Pharmaceuticals Announces Publication of Positive Effects of Add-on Circadin® in Alzheimer’s Disease Patients (Read more)

  • Feb 22, 2012

    Neurim Pharmaceuticals reports the results of stabilometric study of Circadin® demonstrating maintenance of postural stability (Read more)

  • Jul 24, 2011

    Neurim Pharmaceuticals reports the results of stabilometric study of Circadin® demonstrating maintenance of postural stability (Read more)

  • Jun 22, 2011

    Neurim Pharmaceuticals is currently performing a clinical trial in Korea to obtain Circadin® marketing authorization

  • Jun 16, 2011

    Circadin® receives marketing authorization in New Zealand

  • May 17, 2011

    Circadin® use approved for up to 3 months in Switzerland

  • Apr 4, 2011

    Circadin® use approved for up to 3 months in Hong Kong

  • Jan 4, 2011

    TGA approves Circadin® use for up to 3 months

  • Oct 4, 2010

    Circadin® use approved for up to 3 months in Macedonia

  • Sep 6, 2010

    Circadin® use approved for up to 3 months in Croatia

  • Jul 5, 2010

    Circadin® approved in the EU for treatment of Primary Insomnia in patients aged 55 or over for up to 3 months (Read more)

  • News & Views

    • Dr. Zach Pearl

      Circadin.com Staff

    • June, 2017
    • Melatonin’s effects on Cancer

    • Read More
Circadin